CD117 expression is a predictive marker for poor prognosis in patients with non‑small cell lung cancer

Sakabe,Tomohiko; Azumi,Junya; Haruki,Tomohiro; Umekita,Yoshihisa; Nakamura,Hiroshige; Shiota,Goshi

doi:10.3892/ol.2017.5925

CD117 expression is a predictive marker for poor prognosis in patients with non‑small cell lung cancer

Authors:
- Tomohiko Sakabe
- Junya Azumi
- Tomohiro Haruki
- Yoshihisa Umekita
- Hiroshige Nakamura
- Goshi Shiota
View Affiliations

Affiliations: Division of Molecular and Genetic Medicine, Department of Medicine and Regenerative Therapeutics, Graduate School of Medicine, Tottori University, Yonago, Tottori 683‑8504, Japan, Division of General Thoracic Surgery, Tottori University Hospital, Yonago, Tottori 683‑8504, Japan, Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8504, Japan
Published online on: March 27, 2017 https://doi.org/10.3892/ol.2017.5925
Pages: 3703-3708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5‑year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117‑positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self‑renewal and chemoresistance. Therefore, the present study hypothesized that if CD117‑positive cells are CSC‑like cells, CD117 positivity may be associated with the prognosis of patients with NSCLC. To confirm this hypothesis, the association between CD117 expression in patients with NSCLC and clinicopathological characteristics was investigated. CD177 expression was examined by immunohistochemistry in 99 patients with NSCLC who underwent curative surgical resection. Tumor samples in the present study included 73 samples of adenocarcinoma and 26 of squamous carcinoma. The associations of CD177 expression with clinicopathological features and prognosis were examined. The lymph node metastasis and rates of recurrence were significantly associated with overall survival rates through multivariate analysis (P<0.001 and P<0.001), respectively. A Kaplan‑Meier analysis for relapse‑free survival and the log‑rank test revealed that the patients with CD117‑positive cell populations exhibited shorter relapse‑free survival rates compared with patients whose cells were CD117‑negative (P=0.014). The multivariate analysis demonstrated that venous invasion, pathological stage, and CD117 expression were independent prognostic parameters for relapse‑free survival in patients with NSCLC (P=0.001, P=0.001 and P=0.002), respectively. In conclusion, these data suggest that CD117 expression in NSCLC may serve as a useful marker for predicting the prognosis of patients with NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, et al: Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 13:515–524. 2015.PubMed/NCBI
3	Langer CJ, Besse B, Gualberto A, Brambilla E and Soria JC: The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 28:5311–5320. 2010. View Article : Google Scholar : PubMed/NCBI
4	Davidson MR, Gazdar AF and Clarke BE: The pivotal role of pathology in the management of lung cancer. J Thorac Dis. 5:(Suppl 5). S463–S478. 2013.PubMed/NCBI
5	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES and Getz G: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
10	Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L and Cadranel J: Neutrophil alveolitis in bronchioloalveolar carcinoma: Induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol. 152:83–92. 1998.PubMed/NCBI
11	Murdoch C, Muthana M, Coffelt SB and Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
12	Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al: Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 16:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
13	Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A: Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6:3341–3351. 1987.PubMed/NCBI
14	Hirota S: Gastrointestinal stromal tumors: Their origin and cause. Int J Clin Oncol. 6:1–5. 2001. View Article : Google Scholar : PubMed/NCBI
15	Naeem M, Dahiya M, Clark JI, Creech SD and Alkan S: Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol. 33:1182–1187. 2002. View Article : Google Scholar : PubMed/NCBI
16	Micke P, Basrai M, Faldum A, Bittinger F, Rönnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R and Hengstler JG: Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications. Clin Cancer Res. 9:188–194. 2003.PubMed/NCBI
17	Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 6:3319–3326. 2000.PubMed/NCBI
18	Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE and Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19:3521–3528. 2000. View Article : Google Scholar : PubMed/NCBI
19	Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, Lokshin A and Gorelik E: Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 70:338–346. 2010. View Article : Google Scholar : PubMed/NCBI
20	Donnenberg AD, Zimmerlin L, Landreneau RJ, Luketich JD and Donnenberg VS: KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PloS One. 7:e528852012. View Article : Google Scholar : PubMed/NCBI
21	Yang F, Cao L, Sun Z, Jin J, Fang H, Zhang W and Guan X: Evaluation of breast cancer stem cells and intratumor stemness heterogeneity in triple-negative breast cancer as prognostic factors. Int J Biol Sci. 12:1568–1577. 2016. View Article : Google Scholar : PubMed/NCBI
22	Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F and Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 62:1212–1218. 2008. View Article : Google Scholar : PubMed/NCBI
23	Hassan HT: c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res. 33:5–10. 2009. View Article : Google Scholar : PubMed/NCBI
24	Alamgeer M, Peacock CD, Matsui W, Ganju V and Watkins DN: Cancer stem cells in lung cancer: Evidence and controversies. Respirology. 18:757–764. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA and Boyd JA: Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. Cancer. 115:5218–5227. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, et al: Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res. 70:6639–6648. 2010. View Article : Google Scholar : PubMed/NCBI
27	Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
28	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
29	Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 126:950–958. 2010.PubMed/NCBI
30	Cui F, Wang J, Chen D and Chen YJ: CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep. 25:701–708. 2011.PubMed/NCBI